Biosensors   

Biosensor Latest Results

The mgmt of Bisosenors have not given a difinite date on CE mark approval, but they have said that it is aquestion of  'when' and not 'if'.

The mkt is probably worried about  them not getting the CE mark - hence the recent price weakness.

Citigroup has just come out with a report talking abt J & J's takeover of Conors, and they say that it is possible that Biosensor may be played up because of this.

Whatever it is, it is best to be careful on this stk - quite speculative at the moment.

 

It seems that CE approval has been submitted for quite some time already and source said that by end 2006. Anyone know when will the likely date?  Only 6 more weeks to the end of 2006.  Should be pretty soon right?

 

In the case of Conors - it has a unique stent technology, where the drug and polymer is stored on small indentations (called 'reservoirs') on the stent surface, whereby, the stent is able to deliver multiple drugs, as well as control the direction of delivery of the drug, plus its current drug eluting stent (DES) has a biodegradable polymer, which makes it attractive to J & J.

Whether Biosensors will be attractive as a takeover target depends on its current technology. It has a proprietary drug and biodegradable polymer, which seems to be as good as the current commercial products, albeit with biodegradable polymer (it is the in-thing to be biodegradable), but a lot of companies out there are also racing ahead with new technologies, like biodegradable stents !, etc.

I would say that Biosensors is probably ahead of most of the competition in the biodegradable area, but unfortunately, they have yet to receive the CE Mark approval to start marketing their product, in Europe - the place where most companies will start first. (in mkting the product, that is).

 

Does that means Biosensors has the potential for being bought over by bigger company?

 

Johnson & Johnson is buying over Conors Medsystem in the States for US$1.4 billion. Conors has a similar product to Biosensors - ie a biodegradable polymer, in their drug eluting stent. Currently, at this price, the mkt cap of Biosensors is only abt US$500-600 million.

 

price is rising~ wat's the news?

 

Hi, its seems that they are stable but the price is slipping slowly any apparent reason for it? U guys think is still good to hold?

 

from CIMB research:

Maintain Underperform and target price of S$0.76. Target price is based on probability-based DCF valuation (WACC:10%, flat terminal growth). We believe that risks (USFDA approval and commercialisation risk) continue to outweight potential opportunities offered by Biosensors at current valuations. Maintain Underperform.Target price is based on probability-based DCF valuation (WACC:10%, flat terminal growth). We believe that risks (USFDA approval and commercialisation risk) continue to outweight potential opportunities offered by Biosensors at current valuations. Maintain Underperform.

 

despite the loss, the counter managed to stay at current level, but lower than the recent high of 0.955. I think it has taken account into the latest result so should have limited down side.

 

It is often said that when the good news comes out, the situation cannot, for the time being, be any better. So there won't be buyers, since buyers are driven by good news. Hence the price drops! :)

Maybe it's as simple as that.

Trade With Care


-------------   

 

LMA posted better third quarter results, yet the share has nosedived after the results were announced.  Biosensors will experience the same fate.  Beware - manipulators at work - by purposely selling down so as to be able to collect the shares at lower prices when other dump them. Shame to the "manipulators" of both LMA and Biosensors - both fundamentally sound yet have been lying low for some time.

 

Possibly on downtrend now. Bollinger bands really tight too... indicating a sudden price change downwards? Cautious...

 

NEWS RELEASE

Biosensors Reports Increases in Product Revenue for

Fiscal ?07 Second Quarter and First Half

Singapore, 9 November 2006 - Biosensors International Group, Ltd. (?Biosensors? or

the ?Company?, Bloomberg: BIG SP) today reported its second fiscal quarter (?2Q

FY07?) and fiscal half year ended September 30, 2006 (?1H FY07?) financial results.

Total product revenue increased by 16 percent to US$8.2 million in 2Q FY07 from

US$7.0 million in the prior corresponding quarter, and increased by 25 percent to

US$16.1 million for the half year ending September 30, 2006 from US$12.9 million in the

prior fiscal half year. The increases are primarily due to growth in sales of its AxxionTM- Biosensors International Group, Ltd. (?Biosensors? or

the ?Company?, Bloomberg: BIG SP) today reported its second fiscal quarter (?2Q

FY07?) and fiscal half year ended September 30, 2006 (?1H FY07?) financial results.

Total product revenue increased by 16 percent to US$8.2 million in 2Q FY07 from

US$7.0 million in the prior corresponding quarter, and increased by 25 percent to

US$16.1 million for the half year ending September 30, 2006 from US$12.9 million in the

prior fiscal half year. The increases are primarily due to growth in sales of its AxxionTMTM

drug-eluting stent. Revenue from drug-eluting stents was US$3.0 million in the quarter

compared with US$1.9 million in the prior year?s corresponding quarter, an increase of

58%. For the fiscal half year, revenue from drug-eluting stents increased by 161% to

US$6.2 million compared to US$2.4 million in the prior fiscal half year.

?Biosensors? drug-eluting stent technology, particularly our biodegradable polymer

technology, continued to be highlighted at this year?s Transcatheter Cardiovascular

Therapeutics (?TCT?) symposium, held in Washington D.C. last week,? said Mr. Yoh-

Chie Lu, Chairman and CEO of Biosensors. ?During the symposium, safety concerns

associated with first generation drug-eluting stents with non-biodegradable polymer

carriers continued to be an active topic of discussion among leading cardiologists. In the

opinion of some cardiologists, the use of a biodegradable polymer may provide a viable

alternative to treat coronary artery disease in the face of such safety concerns,? he

added.

......